Kevin Smith

Title: Kevin Smith: Innovator in Intranasal Pharmaceutical Dosage Forms

Introduction

Kevin Smith is a notable inventor based in Cambridge, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of intranasal dosage forms. His work focuses on addressing critical health issues, such as opioid overdosing.

Latest Patents

Kevin Smith holds a patent for "Intranasal pharmaceutical dosage forms comprising naloxone." This invention relates to an intranasal pharmaceutical dosage form that includes a dosing unit containing naloxone or a pharmaceutically acceptable salt thereof. The dosage is equivalent to ≥0.5 mg naloxone HCl dissolved in an application fluid of a volume of ≤250 μl. This innovative formulation is designed for use in the treatment of opioid overdosing and its associated symptoms.

Career Highlights

Throughout his career, Kevin has worked with various organizations, including Harm Reduction Therapeutics, Inc. and Euro-Celtique S.A. His experience in these companies has allowed him to refine his expertise in pharmaceutical innovations.

Collaborations

Kevin has collaborated with notable professionals in his field, including Alexander Oksche and Stephen Harris. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Kevin Smith's work in intranasal pharmaceutical dosage forms represents a significant advancement in the treatment of opioid overdosing. His innovative approach and dedication to improving health outcomes highlight the importance of continued research and development in the pharmaceutical industry.